A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass

Gynecologic Oncology

Volumn 138, Issue 3, 2015, Pages 640-646

  Karlsen, Mona A ^a   Høgdall, Estrid V S ^a   Christensen, Ib J ^a,b   Borgfeldt, Christer ^c   Kalapotharakos, Grigorios ^c   Zdrazilova Dubska, Lenka ^d   Chovanec, Josef ^d   Lok, Christianne A R ^e   Stiekema, Anna ^e   Mutz Dehbalaie, Irene ^f   Rosenthal, Adam N ^g,h   Moore, Elizabeth K ⁱ   Schodin, Beth A ^j   Sumpaico, Walfrido W ^k   Sundfeldt, Karin ^l   Kristjansdottir, Björg ^l   Zapardiel, Ignacio ^m   Høgdall, Claus K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^j ABBOTT LABORATORIES   (United States)

^k Manila Central University   (Philippines)

^l UNIVERSITY OF GOTHENBURG   (Sweden)

^m HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

Age; Biomarkers; CA125; Copenhagen Index; CPH I; HE4; Ovarian cancer; Tumor markers

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; COMPARATIVE STUDY; COPENHAGEN INDEX; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; OBSTETRIC PATIENT; OVARY CANCER; PATIENT REFERRAL; PRIORITY JOURNAL; RISK OF MALIGNANCY INDEX; RISK OF OVARIAN MALIGNANCY ALGORITHM; ADOLESCENT; AGE; ALGORITHM; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; METABOLISM; MULTIVARIATE ANALYSIS; OVARIAN DISEASES; OVARIAN NEOPLASMS; PATHOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOMARKERS, TUMOR; CA-125 ANTIGEN; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; OVARIAN DISEASES; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; PROTEINS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84941425257     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.06.021     Document Type: Article

References (33)

1. C.C. Earle, D. Schrag, B.A. Neville, K.R. Yabroff, M. Topor, A. Fahey, and et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients J. Natl. Cancer Inst. 98 3 2006 172 180 (Epub 2006/02/02)
2. K.C. Giede, K. Kieser, J. Dodge, and B. Rosen Who should operate on patients with ovarian cancer? An evidence-based review Gynecol. Oncol. 99 2 2005 447 461 (Epub 2005/08/30)
3. S. Kumpulainen, T. Kuoppala, A. Leminen, J. Penttinen, U. Puistola, E. Pukkala, and et al. Surgical treatment of ovarian cancer in different hospital categories - a prospective nation-wide study in Finland Eur. J. Cancer 42 3 2006 388 395 (Epub 2006/01/18)
4. T. Paulsen, K. Kjaerheim, J. Kaern, S. Tretli, and C. Trope Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals Int. J. Gynecol. Cancer 16 Suppl. 1 2006 11 17 (Epub 2006/03/07)
5. C.L. Fago-Olsen, C. Hogdall, H. Kehlet, I.J. Christensen, and B. Ottesen Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey Acta Obstet. Gynecol. Scand. 90 3 2011 273 279 (Epub 2011/02/11)
6. Retningslinier for visitation, diagnostik og kontrol af epithelial ovarie-, tuba- og primær peritonealcancer samt borderlinetumorer [database on the Internet] 2009 DGC
7. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, T. Verch, and et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol. Oncol. 108 2 2008 402 408 (Epub 2007/12/07)
8. K. Holcomb, Z. Vucetic, M.C. Miller, and R.C. Knapp Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women Am. J. Obstet. Gynecol. 205 4 2011 (358 e1-6. Epub 2011/07/05)
9. I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J.A. Ledbetter, M. Schummer, M. McIntosh, and et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res. 63 13 2003 3695 3700 (Epub 2003/07/04)
10. R.G. Moore, D.S. McMeekin, A.K. Brown, P. DiSilvestro, M.C. Miller, W.J. Allard, and et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol. Oncol. 112 1 2009 40 46 (Epub 2008/10/15)
11. T. Van Gorp, I. Cadron, E. Despierre, A. Daemen, K. Leunen, F. Amant, and et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm Br. J. Cancer 104 5 2011 863 870 (Epub 2011/02/10)
12. M. Montagnana, E. Danese, O. Ruzzenente, V. Bresciani, T. Nuzzo, M. Gelati, and et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin. Chem. Lab. Med. 49 3 2011 521 525 (Epub 2011/02/04)
13. M.A. Karlsen, N. Sandhu, C. Hogdall, I.J. Christensen, L. Nedergaard, L. Lundvall, and et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass Gynecol. Oncol. 127 2 2012 379 383 (Epub 2012/07/28)
14. Y.M. Kim, D.H. Whang, J. Park, S.H. Kim, S.W. Lee, H.A. Park, and et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population Clin. Chem. Lab. Med. 49 3 2011 527 534 (Epub 2011/02/16)
15. M.T. Sandri, F. Bottari, D. Franchi, S. Boveri, M. Candiani, S. Ronzoni, and et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome Gynecol. Oncol. 128 2 2013 233 238 (Epub 2012/12/04)
16. K. Partheen, B. Kristjansdottir, and K. Sundfeldt Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass J. Gynecol. Oncol. 22 4 2011 244 252 (Epub 2012/01/17)
17. C. Anton, F.M. Carvalho, E.I. Oliveira, G.A. Maciel, E.C. Baracat, and J.P. Carvalho A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses Clinics (Sao Paulo) 67 5 2012 437 441 (Epub 2012/06/06)
18. G. Ruggeri, E. Bandiera, L. Zanotti, S. Belloli, A. Ravaggi, C. Romani, and et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm Clin. Chim. Acta 412 15-16 2011 1447 1453 (Epub 2011/05/12)
19. K.K. Chan, C.A. Chen, J.H. Nam, K. Ochiai, S. Wilailak, A.T. Choon, and et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass Gynecol. Oncol. 128 2 2013 239 244 (Epub 2012/10/16)
20. N. Bolstad, M. Oijordsbakken, K. Nustad, and J. Bjerner Human epididymis protein 4 reference limits and natural variation in a Nordic reference population Tumour Biol. 33 1 2012 141 148 (Epub 2011/11/23)
21. N. Urban, J. Thorpe, B.Y. Karlan, M.W. McIntosh, M.R. Palomares, M.B. Daly, and et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer Cancer Epidemiol. Biomark. Prev. 21 11 2012 2087 2094 (Epub 2012/09/11)
22. R.G. Moore, M.C. Miller, E.E. Eklund, K.H. Lu, R.C. Bast Jr., and G. Lambert-Messerlian Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age Am. J. Obstet. Gynecol. 206 4 2012 (349 e1-7. Epub 2012/02/04)
23. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat. Clin. Pract. Oncol. 2 8 2005 416 422 (Epub 2005/09/01)
24. A. Stiekema, C.A. Lok, G.G. Kenter, W.J. van Driel, A.D. Vincent, and C.M. Korse A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer Gynecol. Oncol. 132 3 2014 573 577 (Epub 2014/01/15)
25. G. Kalapotharakos, C. Asciutto, E. Henic, B. Casslen, and C. Borgfeldt High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer J. Ovarian Res. 5 1 2012 20 (Epub 2012/08/23)
26. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat. Med. 15 4 1996 361 387 (Epub 1996/02/28)
27. F. Hakansson, E.V. Hogdall, L. Nedergaard, L. Lundvall, S.A. Engelholm, A.T. Pedersen, and et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass Acta Obstet. Gynecol. Scand. 91 4 2012 496 502 (Epub 2012/01/11)
28. J. Kaijser, A. Sayasneh, K. Van Hoorde, S. Ghaem-Maghami, T. Bourne, D. Timmerman, and et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis Hum. Reprod. Update 20 3 2014 449 462 (Epub 2013/12/9)
29. N. Sandhu, M.A. Karlsen, C. Hogdall, I.A. Laursen, I.J. Christensen, and E.V. Hogdall Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer Scand. J. Clin. Lab. Invest. 74 6 2014 477 484 (Epub 2014/04/13)
30. S. Kondalsamy-Chennakesavan, A. Hackethal, D. Bowtell, and A. Obermair Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age Gynecol. Oncol. 129 3 2013 467 471 (Epub 2013/03/19)
31. N.S. Karlsen, M.A. Karlsen, C.K. Hogdall, and E. Hogdall HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumours - a systematic review Cancer Epidemiol. Biomark. Prev. 23 11 2014 2285 2295 (Epub 2014/08/28)
32. J. Kappelmayer, P. Antal-Szalmas, and B. Nagy Jr. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders Clin. Chim. Acta 438C 2014 35 42 (Epub 2014/08/17)
33. A. Stiekema, Q.J. Boldingh, C.M. Korse, V. van der Noort, H. Boot, W.J. van Driel, and et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin Gynecol. Oncol. 136 3 2015 562 566 (Epub 2015/01/07)